Full-Time

Quality Control Microbiology Senior Specialist

Updated on 9/4/2026

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma focused on antibodies

Compensation Overview

$116k - $152.3k/yr

+ Annual bonus + Long-term incentive program

Sanford, NC, USA

Remote

Requires up to 10% domestic and limited international travel.

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
Veeva
ERP
Risk Management
Microbiology

Get referred to Kyowa Kirin

See people who can refer or advise you

Requirements
  • A minimum bachelor's degree in Microbiology, Biotechnology, or life sciences is required.
  • At least 5 years of experience in a Quality Control Microbiology laboratory providing technical and compliance leadership within GxP biopharmaceutical manufacturing operations is required.
  • Experience leading and conducting investigations of microbial contamination incidents and laboratory nonconformances, including out-of-specification results, is required.
  • In-depth understanding of the Quality Management System and Laboratory Controls subsystem, as well as relevant regulatory standards, is required.
  • Experience participating as a Quality Control Microbiology subject matter expert in regulatory agency inspections of biopharmaceutical manufacturing facilities and supporting areas is required.
  • Proficiency in Microsoft Office Suite and Lean Labs or Agile Lean is required.
Responsibilities
  • Provide technical and compliance leadership for business processes within the Quality Control Microbiology scope.
  • Collaborate cross-functionally on early-stage site activities, including user requirements, equipment and instrument implementation, analytical methods, and electronic Quality Systems such as LIMS, ELN, and LES.
  • Qualify, transfer, and perform compendial and non-routine microbiological methods and procedures in a GxP environment, including bioburden, bacterial endotoxins, growth promotion, microbial identification, and rapid microbiological methods.
  • Apply expertise in sampling, culturing, microscopy, and aseptic techniques.
  • Establish and maintain site Quality Control procedures using the global electronic Quality Management System in Veeva, and develop GxP training requirements for Quality Control staff.
  • Establish a site risk-management procedure for documenting risk-based approaches and decisions with fact- and data-supported rationales.
  • Lead cross-functional implementation of site GxP procedures supporting the Environmental and Utility Monitoring Program and Contamination Control Strategy.
  • Design and implement a site procedure for investigating objectionable microorganisms.
  • Train and qualify team members in microbiology methods across validation samples, water, air, gases, raw materials, surfaces, in-process samples, drug-substance release, stability, and investigations.
  • Provide technical leadership for facility and utility Environmental Monitoring Performance Qualification to ensure facility readiness and compliant production.
  • Review and approve validation and qualification activities for facilities, equipment, analytical instruments, and computerized systems required for commissioning and operational readiness.
  • Ensure compliance with Data Integrity and 21 CFR Part 11 requirements for paper and electronic records.
  • Assist the Senior Manager of Quality Control by onboarding, training, leading, and mentoring junior Quality Control Microbiologists, cross-functional staff, and contractors.
  • Coordinate, schedule, and assign sampling and testing tasks, and review and approve Quality Control laboratory results.
  • Establish laboratory operating processes for gowning, personnel and material flow, sample handling, inventory, safety, waste management, disposal, and cleaning.
  • Prepare laboratory reports and communicate results and findings, including microbial trends, environmental and utility monitoring recoveries and excursions, out-of-specification results, and invalid assays.
  • Collaborate with Operations, Quality Assurance, Quality Systems, and Compliance on policy alignment, inspection readiness, and compliance responses.
  • Lead investigations of nonconformances, deviations, laboratory exceptions, and other current Good Manufacturing Practice issues, and initiate and communicate corrective and preventive actions.
  • Establish key performance indicators for site Quality metrics, including deviations, corrective and preventive actions, change controls, out-of-specification results, invalid assays, out-of-trend results, equipment failures, environmental monitoring trends, stability trends, and product disposition cycle times.
  • Provide subject-matter expertise and leadership to establish a quality culture centered on patient focus, sustainable compliance, and inspection readiness.
  • Develop, approve, monitor, and communicate progress against goals to site leadership and key stakeholders.
Desired Qualifications
  • A master's degree in Microbiology or a related life science is preferred.
  • Experience starting up a new facility and providing Quality Control Microbiology expertise, including facility design reviews and user-requirements reviews, is a plus.
  • Experience defining computerized systems requirements for manufacturing systems such as MES, ERP, electronic batch records, LIMS, Engineering systems such as CMMS, eVAL, and BMS, and laboratory systems such as LIMS, ELN, and LES is a plus.
  • Experience reviewing and contributing to engineering plans and GxP documentation for equipment, facility, and process qualification efforts is a plus, including validation protocols, validation reports, test plans, Project Verification Plans, Validation Master Plans, and Site Master Files.

1) What does this company do? Kyowa Kirin develops specialty pharmaceutical drugs with a focus on nephrology, oncology, and immunology, built on a foundation of fermentation technology and antibody science. 2) How does this company's product(s) work? It uses fermentation-derived biology and antibody-based approaches to create therapies that target kidney disease, cancer, and immune-related conditions, delivered as approved medicines after research, development, and clinical testing. 3) How is this company different from its competitors? It blends deep fermentation and microbiology expertise with antibody technology from its history, plus a global specialty-drug focus, resulting from a merger of Kyowa Hakko Kogyo and Kirin Pharma that combined fermentation know-how with pharmaceutical resources. 4) What is this company's goal? To develop and commercialize innovative treatments that address unmet medical needs in nephrology, oncology, and immunology on a global scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Get referred to Kyowa Kirin

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA selected Sanford for PreCheck on June 30, 2026, accelerating biologics launch readiness.
  • Crysvita expanded adult XLH dosing in May 2026, extending treatment uptake and persistence.
  • 2025 revenue reached ¥496.8 billion, and 2026 guidance rises to ¥520.0 billion.

What critics are saying

  • Crysvita sales still dominate; any reimbursement squeeze or safety issue hits 2026 results fast.
  • Sanford slips past 2027, and the FDA PreCheck advantage evaporates into delay and cost.
  • March 2026 leadership turnover, including CFO Motohiko Kawaguchi, disrupts execution and accountability.

What makes Kyowa Kirin unique

  • Crysvita remains the only approved XLH therapy, protecting a rare-disease franchise in 2026.
  • Sanford, North Carolina gives Kyowa Kirin a first U.S. biologics manufacturing base by 2027.
  • Benchling deployment in Tokyo and Fuji formalizes AI-enabled R&D workflows across discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-2%
Yahoo Finance
Aug 26th, 2026
Cognizant wins Kyowa Kirin AI R&D deal to implement Benchling platform in Japan

Cognizant Technology Solutions will support Kyowa Kirin in implementing Benchling, an AI-driven R&D platform, at the Tokyo and Fuji Research Parks in Japan. The engagement includes platform setup, data migration, ongoing maintenance, and workflow optimization for drug discovery research. The deal reinforces Cognizant's enterprise-scale AI automation capabilities in life sciences digitalization. However, it is unlikely to shift near-term catalysts around broader AI adoption or risks that AI may erode demand for labour-intensive services. Cognizant's narrative projects $24.9 billion revenue and $3.1 billion earnings by 2029, requiring 5.2% yearly revenue growth. The most optimistic analysts forecast revenue reaching $26.1 billion and earnings of $3.9 billion by 2029, depending on how AI investments translate into higher-margin work.

IT Business Today
Aug 17th, 2026
Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation.

Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation. Last updated: August 17, 2026 12:53 pm Kyowa Kirin has chosen Cognizant and Benchling to support the rollout of Benchling's cloud-based R&D platform at its Tokyo Research Park and Fuji Research Park. The platform brings experimental planning, data collection, AI tools, and workflow automation into one place. Researchers can connect experimental equipment directly to Benchling, allowing data to be captured as structured and searchable records instead of being entered manually. That matters as Kyowa Kirin's research work becomes more complex and its pipeline expands. The company expects the platform to help speed up activities ranging from identifying drug targets to selecting new drug candidates. Researchers will also be able to search past experiments, generate reports, examine relationships between studies, and support molecular design using the platform's analytical and AI capabilities. Cognizant will handle the implementation using Benchling, including platform setup, data migration, deployment, and the ongoing upkeep too. This partnership shows where pharma research and development is headed, more or less, these days. More of the work around data handling and routine processes is being moved into connected digital systems, while AI is being brought closer to the research itself rather than treated as a separate tool. ITBT Staffwriter is an in-house contributor at IT Business Today, responsible for delivering timely News and QuickBytes. The author covers the latest developments across IT, tech, and enterprise solutions to keep readers informed with concise and impactful updates. August 17, 2026

Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.